The Impact of TAILORx study on the recommendation of chemotherapy- the Warwick experience
Association of Breast Surgery ePoster Library. Sein T. 05/13/19; 257141; P097
Mr. Tin Sein
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P097
Topic: Non surgical treatments
Background: The Oncotype DX breast cancer assay provides a marker for risk of distant recurrence and patients in the intermediate risk group were often advised chemotherapy. The TAILORx study showed, in patients over 50 with a risk score of less than 25 and in patients younger than 50, with a risk score less than 20, that chemotherapy could be spared.AimThe aim of this study was to determine the utilisation of chemotherapy use based on the Oncotype DX risk score in the intermediate group and the projected reduction in chemotherapy utilisation after adoption of TAILORxrecommendations.MethodologyConsecutive patients with low clinical risk that had undergone Oncotype DX testing from February 2012 to May 2018 were reviewed. Baseline information including patient demographics, tumour characteristics and chemotherapy was recorded.The data was then reviewed in light of the TAILORx study results to project the potential reduction in chemotherapy use. Results143 patients were identified, with 83 being over 50. Of these, 41 patients had an intermediate recurrence score of 11-25 and 15(37%) of these patients were advised chemotherapy and 11 received chemotherapy.60 patients were under 50 years. Of these patients 26 patients had a recurrence scores 11-20 and of these 6 (23%) patients were advised and received chemotherapy.ConclusionBy adopting the TAILORx recommendations there will be a reduction in patients offered chemotherapy.
Topic: Non surgical treatments
Background: The Oncotype DX breast cancer assay provides a marker for risk of distant recurrence and patients in the intermediate risk group were often advised chemotherapy. The TAILORx study showed, in patients over 50 with a risk score of less than 25 and in patients younger than 50, with a risk score less than 20, that chemotherapy could be spared.AimThe aim of this study was to determine the utilisation of chemotherapy use based on the Oncotype DX risk score in the intermediate group and the projected reduction in chemotherapy utilisation after adoption of TAILORxrecommendations.MethodologyConsecutive patients with low clinical risk that had undergone Oncotype DX testing from February 2012 to May 2018 were reviewed. Baseline information including patient demographics, tumour characteristics and chemotherapy was recorded.The data was then reviewed in light of the TAILORx study results to project the potential reduction in chemotherapy use. Results143 patients were identified, with 83 being over 50. Of these, 41 patients had an intermediate recurrence score of 11-25 and 15(37%) of these patients were advised chemotherapy and 11 received chemotherapy.60 patients were under 50 years. Of these patients 26 patients had a recurrence scores 11-20 and of these 6 (23%) patients were advised and received chemotherapy.ConclusionBy adopting the TAILORx recommendations there will be a reduction in patients offered chemotherapy.
P097
Topic: Non surgical treatments
Background: The Oncotype DX breast cancer assay provides a marker for risk of distant recurrence and patients in the intermediate risk group were often advised chemotherapy. The TAILORx study showed, in patients over 50 with a risk score of less than 25 and in patients younger than 50, with a risk score less than 20, that chemotherapy could be spared.AimThe aim of this study was to determine the utilisation of chemotherapy use based on the Oncotype DX risk score in the intermediate group and the projected reduction in chemotherapy utilisation after adoption of TAILORxrecommendations.MethodologyConsecutive patients with low clinical risk that had undergone Oncotype DX testing from February 2012 to May 2018 were reviewed. Baseline information including patient demographics, tumour characteristics and chemotherapy was recorded.The data was then reviewed in light of the TAILORx study results to project the potential reduction in chemotherapy use. Results143 patients were identified, with 83 being over 50. Of these, 41 patients had an intermediate recurrence score of 11-25 and 15(37%) of these patients were advised chemotherapy and 11 received chemotherapy.60 patients were under 50 years. Of these patients 26 patients had a recurrence scores 11-20 and of these 6 (23%) patients were advised and received chemotherapy.ConclusionBy adopting the TAILORx recommendations there will be a reduction in patients offered chemotherapy.
Topic: Non surgical treatments
Background: The Oncotype DX breast cancer assay provides a marker for risk of distant recurrence and patients in the intermediate risk group were often advised chemotherapy. The TAILORx study showed, in patients over 50 with a risk score of less than 25 and in patients younger than 50, with a risk score less than 20, that chemotherapy could be spared.AimThe aim of this study was to determine the utilisation of chemotherapy use based on the Oncotype DX risk score in the intermediate group and the projected reduction in chemotherapy utilisation after adoption of TAILORxrecommendations.MethodologyConsecutive patients with low clinical risk that had undergone Oncotype DX testing from February 2012 to May 2018 were reviewed. Baseline information including patient demographics, tumour characteristics and chemotherapy was recorded.The data was then reviewed in light of the TAILORx study results to project the potential reduction in chemotherapy use. Results143 patients were identified, with 83 being over 50. Of these, 41 patients had an intermediate recurrence score of 11-25 and 15(37%) of these patients were advised chemotherapy and 11 received chemotherapy.60 patients were under 50 years. Of these patients 26 patients had a recurrence scores 11-20 and of these 6 (23%) patients were advised and received chemotherapy.ConclusionBy adopting the TAILORx recommendations there will be a reduction in patients offered chemotherapy.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}